Remove Drug Delivery Remove In-Vitro Remove In-Vivo Remove Medicine
article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

As the industry moves to reduce the use of animals in research and testing, aptamers also support here, as they are discovered, developed, and manufactured entirely in vitro , removing the need for animals in antibody discovery processes. AT : The major interest we see is in the targeted delivery of therapeutic molecules.

article thumbnail

What to expect from PEGS Europe 2023: Day 1

Drug Discovery World

Sebastian Jaeger, PhD, Senior Scientist, ADCs & Targeted NBE Therapeutics, Merck Healthcare KGaA, on: ‘Evaluation of Fcab-drug conjugates as a novel antibody-based format for targeted drug delivery’. Marketing Product Manager, Product, NanoTemper Technologies.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.